Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim support study in chemotherapy-treated gynecologic tumors
ChiCTR1900024592Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim and filgrastim in ovarian cancer, Cervical Cancer (CC) and endometrial cancer (EC) (4 arms), sponsored by Tongji Hospital. Primary endpoint: Duration of grade IV agranulocytosis. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR1900024592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024592.